Acurx Pharmaceuticals ACXP

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.18 (-27.94%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Acurx Pharmaceuticals (ACXP)
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $0.4573

  • Market Cap

    $8.93 Million

  • Price-Earnings Ratio

    -0.42

  • Total Outstanding Shares

    19.53 Million Shares

  • Total Employees

    4

  • Dividend

    No dividend

  • IPO Date

    June 25, 2021

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    259 liberty avenue, Staten island, NY, 10305

  • Homepage

    https://www.acurxpharma.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$1.29 Million
Net Cash Flow, Continuing$0
Net Cash Flow$0
Net Cash Flow From Operating Activities, Continuing$-12.33 Million
Net Cash Flow From Operating Activities$-12.33 Million
Net Cash Flow From Financing Activities, Continuing$11.04 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations After Tax$-16.44 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
Other Operating Expenses$9.91 Million
Net Income/Loss Attributable To Noncontrolling Interest$0
Diluted Average Shares$32.43 Million
Income/Loss From Continuing Operations Before Tax$-16.44 Million

Comprehensive Income

October 1, 2023 to September 30, 2024
MetricValue
Other Comprehensive Income/Loss$0
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss$-16.44 Million
Comprehensive Income/Loss Attributable To Parent$-16.44 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Assets$5.98 Million
Other Current Liabilities$3.07 Million
Current Liabilities$3.32 Million
Wages$247,210
Equity Attributable To Noncontrolling Interest$0
Current Assets$5.98 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about ACXP from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.